It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Kelch repeat and BTB domain-containing protein 11 (KBTBD11) is a member of the KBTBD subfamily of proteins that possess a BTB domain and Kelch repeats. Despite the presence of the Kbtbd11 gene in mammalian genomes, there are few reports about KBTBD11 at present. In this study, we identified the novel protein KBTBD11 as a negative regulator of osteoclast differentiation. We found that expression of KBTBD11 increased during osteoclastogenesis. Small-interfering-RNA-mediated knockdown of KBTBD11 enhanced osteoclast formation, and markedly increased the expression of several osteoclast marker genes compared with control cells. Conversely, KBTBD11 overexpression impaired osteoclast differentiation, and decreased the expression of osteoclast marker genes. Among six major signaling pathways regulating osteoclast differentiation, KBTBD11 predominantly influenced the nuclear factor of activated T cell cytoplasmic-1 (NFATc1) pathway. Mechanistically, KBTBD11 was found to interact with an E3 ubiquitin ligase, Cullin3. Further experiments involving immunoprecipitation and treatment with MG132, a proteasome inhibitor, showed that the KBTBD11–Cullin3 promotes ubiquitination and degradation of NFATc1 by the proteasome. Considering that NFATc1 is an essential factor for osteoclast differentiation, the KBTBD11 and Cullin3 probably regulate the levels of NFATc1 through the ubiquitin-proteasome degradation system. Thus, KBTBD11 negatively modulates osteoclast differentiation by controlling Cullin3-mediated ubiquitination of NFATc1.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Graduate School of Biomedical Sciences, Nagasaki University, Department of Dental Pharmacology, Nagasaki, Japan (GRID:grid.174567.6) (ISNI:0000 0000 8902 2273); Graduate School of Biomedical Sciences, Nagasaki University, Department of Regenerative Oral Surgery, Nagasaki, Japan (GRID:grid.174567.6) (ISNI:0000 0000 8902 2273)
2 Graduate School of Biomedical Sciences, Nagasaki University, Department of Dental Pharmacology, Nagasaki, Japan (GRID:grid.174567.6) (ISNI:0000 0000 8902 2273)
3 Graduate School of Biomedical Sciences, Nagasaki University, Department of Frontier Life Science, Nagasaki, Japan (GRID:grid.174567.6) (ISNI:0000 0000 8902 2273)
4 Graduate School of Biomedical Sciences, Nagasaki University, Department of Dental Pharmacology, Nagasaki, Japan (GRID:grid.174567.6) (ISNI:0000 0000 8902 2273); Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Dental Pharmacology, Okayama, Japan (GRID:grid.261356.5) (ISNI:0000 0001 1302 4472)
5 Graduate School of Biomedical Sciences, Nagasaki University, Department of Regenerative Oral Surgery, Nagasaki, Japan (GRID:grid.174567.6) (ISNI:0000 0000 8902 2273)